Literature DB >> 27182210

Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy.

Meghan NeSmith1, Joseph Ahn1, Steven L Flamm1.   

Abstract

Hepatic encephalopathy (HE) is a major complication of liver disease that leads to significant morbidity and mortality. Caring for hospitalized patients with HE is becoming more complex, and the economic burden of HE continues to rise. Defining and diagnosing HE, particularly covert HE (CHE), remain challenging. In this article, we review new tools and those currently under development for the diagnosis of CHE and the latest advances in the acute and long-term management of overt HE (OHE) and CHE. In particular, we review the latest data on the use of lactulose and rifaximin for treatment of OHE and summarize the data on adjunctive agents such as sodium benzoate and probiotics.

Entities:  

Keywords:  Hepatic encephalopathy; covert hepatic encephalopathy; lactulose; overt hepatic encephalopathy; rifaximin

Year:  2016        PMID: 27182210      PMCID: PMC4865778     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  47 in total

Review 1.  Probiotics for patients with hepatic encephalopathy.

Authors:  Richard G McGee; Anouk Bakens; Kerrie Wiley; Stephen M Riordan; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

2.  Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy.

Authors:  Tarek Hassanein; Andres T Blei; William Perry; Robin Hilsabeck; Jan Stange; Fin S Larsen; Robert S Brown; Stephen Caldwell; Brendan McGuire; Frederik Nevens; Robert Fontana
Journal:  Am J Gastroenterol       Date:  2009-06       Impact factor: 10.864

3.  Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.

Authors:  Antoni Mas; Juan Rodés; Lourdes Sunyer; Luís Rodrigo; Ramon Planas; Victor Vargas; Lluís Castells; Dolores Rodríguez-Martínez; Conrado Fernández-Rodríguez; Ignasi Coll; Albert Pardo
Journal:  J Hepatol       Date:  2003-01       Impact factor: 25.083

4.  Electroencephalography in patients with cirrhosis.

Authors:  Piergiorgio Marchetti; Costanza D'Avanzo; Raffaele Orsato; Sara Montagnese; Sami Schiff; Peter W Kaplan; Francesco Piccione; Carlo Merkel; Angelo Gatta; Giovanni Sparacino; Gianna Maria Toffolo; Piero Amodio
Journal:  Gastroenterology       Date:  2011-07-18       Impact factor: 22.682

5.  Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy.

Authors:  M Romero-Gómez; F Boza; M S García-Valdecasas; E García; J Aguilar-Reina
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

Review 6.  Assessment of minimal hepatic encephalopathy (with emphasis on computerized psychometric tests).

Authors:  Matthew R Kappus; Jasmohan S Bajaj
Journal:  Clin Liver Dis       Date:  2012-02       Impact factor: 6.126

Review 7.  Benzodiazepine receptor antagonists for hepatic encephalopathy.

Authors:  B Als-Nielsen; L L Gluud; C Gluud
Journal:  Cochrane Database Syst Rev       Date:  2004

8.  Diagnosis of covert hepatic encephalopathy without specialized tests.

Authors:  Eiman Nabi; Leroy R Thacker; James B Wade; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Douglas M Heuman; Iliana Bouneva; Arun J Sanyal; Mohammad S Siddiqui; Velimir Luketic; Melanie B White; Pamela Monteith; Nicole A Noble; Ariel Unser; Jasmohan S Bajaj
Journal:  Clin Gastroenterol Hepatol       Date:  2013-12-19       Impact factor: 11.382

9.  Value of critical flicker frequency and psychometric hepatic encephalopathy score in diagnosis of low-grade hepatic encephalopathy.

Authors:  Gerald Kircheis; Norbert Hilger; Dieter Häussinger
Journal:  Gastroenterology       Date:  2013-12-21       Impact factor: 22.682

10.  Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.

Authors:  Barjesh Chander Sharma; Praveen Sharma; Amit Agrawal; Shiv Kumar Sarin
Journal:  Gastroenterology       Date:  2009-06-06       Impact factor: 22.682

View more
  5 in total

Review 1.  A Possible Role of Intestinal Microbiota in the Pathogenesis of Ankylosing Spondylitis.

Authors:  Lianjun Yang; Liping Wang; Xin Wang; Cory J Xian; Hai Lu
Journal:  Int J Mol Sci       Date:  2016-12-17       Impact factor: 5.923

2.  Impaired brain glucose metabolism in cirrhosis without overt hepatic encephalopathy: a retrospective 18F-FDG PET/CT study.

Authors:  Weishan Zhang; Ning Ning; Xianjun Li; Miao Li; Xiaoyi Duan; Youmin Guo; Yaping Dang; Yan Li; Jungang Gao; Jiajun Ye; Jian Yang
Journal:  Neuroreport       Date:  2019-08-07       Impact factor: 1.837

3.  Chinese guidelines on management of hepatic encephalopathy in cirrhosis.

Authors:  Xiao-Yuan Xu; Hui-Guo Ding; Wen-Gang Li; Ji-Dong Jia; Lai Wei; Zhong-Ping Duan; Yu-Lan Liu; En-Qiang Ling-Hu; Hui Zhuang; Chinese Society Of Hepatology; Chinese Medical Association
Journal:  World J Gastroenterol       Date:  2019-09-28       Impact factor: 5.742

Review 4.  The Direct Contribution of Astrocytes and Microglia to the Pathogenesis of Hepatic Encephalopathy.

Authors:  Victoria Jaeger; Sharon DeMorrow; Matthew McMillin
Journal:  J Clin Transl Hepatol       Date:  2019-11-13

5.  Sodium Benzoate Delays the Development of Drosophila melanogaster Larvae and Alters Commensal Microbiota in Adult Flies.

Authors:  Yuling Dong; Zhongfeng Ding; Linxia Song; Desheng Zhang; Changjian Xie; Shujing Zhang; Ling Feng; Hongliang Liu; Qiuxiang Pang
Journal:  Front Microbiol       Date:  2022-06-22       Impact factor: 6.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.